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Background: Human lung mast cells (HLMCs) infiltrate the airway epithelium and airway smooth muscle (ASM) in
asthmatic airways. The mechanism of HLMC adhesion to both cell types is only partly defined, and adhesion is not
inhibited by function-blocking anti-Kit and anti-stem cell factor (SCF) antibodies. Our aim was to identify adhesion molecules
expressed by human mast cells that mediate adhesion to human ASM cells (HASMCs) and human airway epithelial cells.
Methods:We used phage-display to isolate single chain Fv (scFv) antibodies with adhesion-blocking properties from rabbits
immunised with HLMC and HMC-1 membrane proteins.
Results: Post-immune rabbit serum labelled HLMCs in flow cytometry and inhibited their adhesion to human BEAS-2B
epithelial cells. Mast cell-specific scFvs were identified which labelled mast cells but not Jurkat cells by flow cytometry.
Of these, one scFv (A1) consistently inhibited mast cell adhesion to HASMCs and BEAS-2B epithelial cells by about
30 %. A1 immunoprecipitated Kit (CD117) from HMC-1 lysates and bound to a human Kit-expressing mouse mast cell
line, but did not interfere with SCF-dependent Kit signalling.
Conclusion: Kit contributes to human mast cell adhesion to human airway epithelial cells and HASMCs, but may utilise
a previously unidentified adhesion domain that lies outside the SCF binding site. Targeting this adhesion pathway
might offer a novel approach for the inhibition of mast cell interactions with structural airway cells, without detrimental
effects on Kit signalling in other tissues.
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Mast cells (MC) play a significant role in the patho-
physiology of many diverse diseases including asthma
[1]. Interestingly in asthma, MCs infiltrate the airway
smooth muscle (ASM) [2], bronchial epithelium [3] and
submucosal glands [4], and within these sites demonstrate
features of activation. MC mediator release therefore oc-
curs within these dysfunctional airway elements and has a
profound effect on airway function, inflammation and re-
modelling [1]. Targeting the interactions between MCs* Correspondence: pb46@le.ac.uk
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offer a novel approach to the treatment of asthma.
Adhesion is a fundamental mechanism through which
cells communicate allowing the targeting of specific cell-
to-cell signals. Human lung mast cells (HLMC) and the
immature leukaemic human MC line HMC-1 adhere
avidly to both primary human ASM cells (HASMCs) [5]
and primary human airway epithelial cells [6], and both
MC types display identical adhesion properties [5, 6].
The mechanisms of adhesion however remain poorly
defined. With respect to the bronchial epithelium, the
adhesion mechanism is unknown but does not utilise
recognised integrins and C-type lectins [6]. Similarly,
constitutive HLMC and HMC-1 adhesion to HASMCs
does not involve recognised integrins or their ligandsrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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sion to HASMCs is partially dependent on Ca2+, and
thus resembles adhesion of skin MCs and HMC-1s to
skin fibroblasts [5, 7]. Of note, human MC-epithelial
and MC-HASMC adhesion were not inhibited by func-
tion blocking anti-Kit (stem cell factor [SCF] receptor,
CD117) or anti-SCF antibodies [5, 6]. However, human
HASMC-MC adhesion is mediated in part via cell adhe-
sion molecule-1 (CADM1) [5], and when HLMCs and
HASMCs are activated with TGFβ and TNFα respectively,
there is enhancement of HLMC adhesion which is medi-
ated via CD51/61 [8].
The importance of these adhesive interactions is dem-
onstrated by observations that HASMCs maintain HLMC
survival and induce their proliferation through a CADM1-
dependent mechanism [9]. Inhibiting adhesion therefore
has great potential for the attenuation of a wide range
of allergic and fibrotic disorders. To further define the
mechanisms mediating HLMC adhesion to HASMCs and
bronchial epithelial cells, we have used the technique of
phage-display to express a library of recombinant anti-
bodies raised against human MC plasma membranes.
Using this technique we have isolated a single chain Fv
(scFv) antibody that binds to Kit but does not modulate
its signalling, and which partially inhibits HMC-1 adhe-
sion to both HASMCs and bronchial epithelium.
Methods
Ethics statement
All patients donating tissue gave written informed consent.
Use of tissue from lung resection was approved by the Na-
tional Research Ethics Service (reference 07/MRE08/42)
and bronchoscopic studies were approved by the Leicester-
shire Research Ethics Committee (reference number 4977).
Human mast cell purification and culture
HLMCs were isolated and cultured as described previously
[6, 10]. Final purity was >99 %, and viability >97 % in all
experiments.
The leukaemic human MC line HMC-1 (Dr J Butterfield,
Mayo Clinic, Rochester, USA) was cultured as described
previously [6].
Human airway smooth muscle cell and BEAS-2B culture
HASMCs were isolated using explant culture of ASM
bundles as previously described [11]. HASMCs were cul-
tured in DMEM supplemented with 10 % FBS, antibiotic/
antimycotic agents and non-essential amino acids [11].
BEAS-2B epithelial cells were purchased from the European
Collection of Animal Cell Cultures (Porton Down,
Wiltshire, UK). Cells (passages 8–12) were grown on
human plasma fibronectin-coated T75 culture flasks in
BEBM media (Clonetics Cat. No. CC4175), with an added
enhancement bullet kit (Clonetics Cat. No. CC4175),Pen/Strep (5 ml) and fungizone (5 ml) to create basal
epithelial growth media (BEGM). BEAS-2B were then
passaged on to human plasma fibronectin-coated 96-well
plates and then grown to confluence prior to use in adhe-
sion assays as described previously [6].
Micro-organisms and plasmids
Escherichia coli XL1-blue (endA1 gyrA96 (nalR) thi-1 recA1
relA1 lac glnV44 F’[::Tn10 proAB+ lacIq Δ (lacZ) M15]
hsdR17 (rK
− mK
+)) and HB2151 (K12, ara, del (lac-pro),
thi/F’proA + B+, lacIq, lacZdelM15) were obtained from
Pharmacia LKB (St Albans, Herts, UK). Gene Hogs compe-
tent cells (F- mcrA Δ (mrr-hsdRMS-mcrBC) φ80lacZΔM15
ΔlacX74 recA1 araD139 Δ (ara-leu) 7697 galU galK rpsL
(StrR) endA1 nupG fhuA::IS2 (confers phage T1 resistance)
were obtained from Invitrogen (Paisley, UK). Ex-12 helper
phage [12] was obtained from Ig Therapy Co. (College of
Agriculture of Life Sciences, Kangwon National University,
Republic of Korea). The construction of the phagemid
vector pSD3 is described by Li et al. [13].
Preparation of HLMC and HMC-1 membranes
HLMCs from several donors were suspended in buffer
(10 mM Tris–HCl, pH 7.4, 1 mM EDTA, 200 mM sucrose,
1 mM phenylmethylsulfonyl fluoride) and homogenized.
The nuclei and cell debris were removed from the hom-
ogenate by centrifugation (900 g, 10 min, 4 °C). The pellet
was washed with buffer and centrifuged (900 g, 10 min).
The resulting supernatants were pooled and centrifuged
(110000 g, 75 min, 4 °C). The supernatant was discarded,
the membrane pellet dissolved in PBS, and protein concen-
tration was measured (Bio-Rad DC protein assay, BioRad,
Hemel Hempstead, UK). 1.54 mg of HLMC membrane
protein was obtained from 6.5 × 107 cells. Using the same
protocol, 4.6 mg of membrane protein was obtained from
1 × 108 HMC-1 cells.
Immunisation of rabbits with mast cell membranes
Two female New Zealand white rabbits were immunised
with a 1 ml mixture of 0.4 mg HLMC membrane protein
in 0.5 ml PBS and 0.5 ml Titermax Gold. Three weeks
later, both rabbits were boosted with a mixture of 0.25 mg
HLMC membrane protein and 0.5 mg HMC-1 membrane
protein. After a further two weeks, both rabbits were
boosted with 0.7 mg HMC-1 membrane protein. After
a further two weeks, both rabbits were boosted with
0.12 mg HLMC membrane protein and 0.5 mg HMC-1
membrane protein. Post-immune sera were labelled R91
and R92.
Experiments using rabbits were carried out within the
Biomedical Services Unit at the University of Leicester,
UK. All animal procedures were performed under Home
Office (UK) and local ethical review committee approval
and compliant with the Animal (Scientific Procedures)
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cages and fed on SDS Stanrab diet. They were on a light
cycle of 12 h light, 12 h dark (7 am-7 pm). Local an-
aesthetic cream was applied prior to blood sampling.
Terminal procedures: overdose of anaesthetic with ex-
sanguination to confirm death.
Generation of an immune rabbit scFv-phage library
Protocols for DNA manipulation were taken from
Sambrook et al. [14] or were those recommended by the
manufacturers. The construction of an immune phage-
display single chain variable region (scFv) antibody library
was carried out as described by Gough et al. [15] and
Kuhne et al. [16]. Briefly, the spleens from both rabbits
were cut into thin pieces, submerged in RNAlater and
stored at 4 °C. Total RNA was isolated from spleen tissue
using a RNA isolation kit (Qiagen, Surrey, UK) and used
in the production of first strand cDNA using a cDNA
synthesis kit (Pharmacia, Herts, UK) and a random hexa-
nucleotide primer. The VL and VH repertoire of the rab-
bits were amplified by PCR. Purified VL PCR products
were cleaved with SfiI and purified VH PCR products
cleaved with PflMI. Cleaved products were purified by gel
extraction and the VL repertoire ligated into SfiI cut pSD3
[13]. VL-pSD3 ligation products were dialysed against ster-
ile water and then 42 ng used to transform GenHogs One-
Shot competent cells. Multiple transformations were
carried out yielding 3 × 106 VL-pSD3 containing cells. VL
fragment diversity was assessed by amplification of the VL
gene using primers pSDF (5’-TATTTCAAGGAGACAGT
C-3’) and pSDseq2 (5’-AACCCACTCCTTGGCCTTC-3’)
followed by digestion of the PCR products with BstNI re-
striction enzyme. Resulting fragments were analysed on a
3 % (w/v) agarose gel. The ‘VL library’ had an estimated
diversity of 2.3 × 106 distinct light chains. The VL-pSD3 li-
brary was cleaved with PflMI and the VH repertoires li-
gated in. Purified pSD3:scFv ligation product (40 ng) was
then used to transform electrocompetent GenHogs One-
Shot cells. ScFv fragment diversity was assessed by ampli-
fication of the scFv gene using primers pSDF and pSDR
(5’-ATTGGCCTTGATATTCAC-3’) followed by analysis
of DNA fragments produced upon BstNI digestion.
Multiple transformations yielded a scFv library consist-
ing of an estimated 3.7 × 107 different antibodies. The
library DNA was purified and transformed into XL1-blue
host cells. The resulting clones coded for scFv-pIII fu-
sion proteins containing poly-Histidine and C-myc
tags between the scFv and pIII domains. An amber top
codon was situated between the C-myc tag and the
pIII gene [13].
Selection of mast cell-specific scFv-displaying phage
Phage were prepared from the rabbit anti-mast cell library
as described by Oh et al. [12] utilising Ex-12 helper phageto rescue scFv-displaying phage. Phage selection was
carried out in solution; HMC-1 cells were pelleted at
500 g and washed twice in RPMI (Sigma, Poole, UK),
re-pelleted and then resuspended in 1 ml Hank’s buffered
salt solution (HBSS, 0.137 M NaCl, 5.4 mM KCl, 0.25 mM
Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM,
MgSO4, 4.2 mM NaHCO3). The phage library was then
depleted of antibodies that display binding to antigens on
the cell surface that are not recognised by the immune
sera; this was carried out by binding the phage scFvs to
HMC-1 cells that had been epitope-masked as described
by Popkov et al. [17]. Briefly, 0.5 ml of the HMC-1 cells
(1-2 × 107 cells) were incubated with 200 μl of a pool of
the anti-mast cell serum R91 and R92 for 30 min at room
temperature before cells were blocked with 2 % (w/v)
Marvel-HBSS for 30 min at RT. Cells were then washed
3 times in HBSS and resuspended in 1 ml of blocked
phage solution. For the initial round of panning, PEG-
precipitated library phage (5 × 1013/ml, 1 ml) were blocked
in 3 % (w/v) Marvel-HBSS for 45 min at RT. For subse-
quent rounds, 1 ml of the supernatant of an overnight bac-
terial culture of phage was used. Blocked phage were
incubated with the epitope-masked HMC-1 cells for 30 min
at room temperature with rotating. Cells were pelleted
(500 g, 5 min) and the phage-containing supernatant
removed (‘depleted phage’). ‘Unmasked’ HMC-1 cells
(1-2 × 107 cells) were blocked in HBSS-3 % (w/v) Marvel
for 30 min at RT. ‘Unmasked’ cells were then pelleted and
resuspended in the ‘depleted phage’ and incubated for 1 h
at RT with rotating. Unbound phage were removed by
washing 3 times with RPMI and 3 times with HBSS;
bound phage were then eluted in 25 mM triethylamine as
described previously [15]. Up to four rounds of iterative
scFv-phage selection were carried out with each round
including a negative selection of phage against
epitope-masked HMC-1 cells followed by a positive
selection against unmasked HMC-1. Monoclonal phage-
displayed scFvs were obtained after 3 or 4 rounds of pan-
ning by plating out the XL1-blue infected cells to single
colonies. Cultures of these single colonies were then used
to produce monoclonal scFv-phage particles by rescue
with Ex-12 helper phage. For the production of soluble
scFvs, monoclonal scFv-phage particles were used to in-
fect HB2151 host cells followed by IPTG induced ex-
pression [15].
Phage-scFv ELISA
Both polyclonal and monoclonal phage preparations were
assayed against HMC-1 cells by ELISA. Polyclonal phage
were assayed at 1 × 1011/ml and monoclonal phage were
assayed using 100 μl of supernatant from an overnight
culture of bacteria following phage rescue. All steps were
carried out within deep well tissue culture plates and the
final step transferred to Nunc Maxisorb ELISA plates
Fig. 1 Binding of post immune rabbit sera to HLMC. Flow cytometry showing that the post immune serum from a rabbit immunised with HLMC/
HMC-1 plasma membranes (bottom row) demonstrates increased binding to HLMC compared to the pre-immune serum (top row) at equivalent
dilutions. Representative of data from two immunised rabbits
Fig. 2 Inhibition of HLMC adhesion to BEAS-2B by post immune
rabbit sera. Adhesion of HLMC to BEAS-2B human bronchial epithelial
cells was attenuated by the post immune serum from two rabbits
(A and B) immunised with HLMC/HMC-1 plasma membranes. n = 5
HLMC donors studied in 5 independent experiments. *p= 0.004 for each
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to be taken. All blocking and wash steps were as in the
panning protocol. Phage-scFv were bound to HMC-1 cells
(~106 cells per well) for 1 h at room temperature, bound
phage were detected in two steps using biotin labelled
anti-fd antibody (1/160) and then extravadin-AP conjugate
(1/10,000; both from Sigma). Signals were developed
with PNPP substrate from Sigma and the absorbance at
405 nm measured.
ScFv purification
Soluble scFv was purified via its poly-His tag on a HisPur
Cobalt resin column as recommended by the manufac-
turers (Pierce). ScFv concentration was estimated using
the BCA protein assay kit (Pierce, Rockford, IL, USA) and
protein purity assessed by analysis by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
Pure scFvs were stored in 37.5 % (v/v) glycerol at −80 °C
at concentrations in the range 0.1 to 0.9 mg/ml.
SDS-PAGE and Western blotting
Discontinuous SDS-PAGE was carried out through a
running gel containing 12 % (w/v) total acrylamide using
NuPAGE pre-cast Bis-Tris gels and Seeblue Plus 2 protein
markers (Invitrogen, Paisley, UK). Electrophoresed gels
were stained using 0.05 % (w/v) Coomassie Brilliant
Blue R250 (Fischer Scientific). For Western blots, sepa-
rated proteins were transferred to polyvinylidine difluoride
membrane (Roche) using a NuPAGE Blot module (Invi-
trogen) at 30 V for 1 h. The 9E10 anti-C-myc antibody
was used to identify scFvs. For staining of Kit in Westernblots, a mouse IgG1 anti human Kit antibody (E1, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used.
Identification of scFv amino acid sequences
ScFv clones were sequenced by dye termination with
AmpliTaq DNA polymerase, FS on a 377 ABI automated
DNA sequencer using the primers pSDF (5’-TATTTCA
AGGAGACAGTC-3’) and pSDR (5’-ATTGGCCTTGA
TATTCAC-3’). The scFv sequences were aligned as
Gough et al. Respiratory Research  (2015) 16:86 Page 5 of 11described by Kabat et al. [18]. The antibodies consisted
of a VH-a1 heavy chain [19] combined with a kappa light
chain.
Flow cytometry
MCBS1 mouse mast cells were a kind gift from Dr Dean
Metcalfe, National Institute for Allergy and Infectious
Diseases, NIH, Bethesda, MD) [20]. Control non trans-
fected cells, mock transfected cells (E1-AA685) or human
Kit-transfected cells (W1-AA677) were stained with 4 ug/
mL PE-labelled anti-Kit mAb (BD Bioscience, Oxford, UK)
or 5 μg/mL A1 scFv antibody followed by 9E10 (anti-myc)
secondary antibody, which was then indirectly labelled with
R-Phycoerythrin (PE)-labelled rabbit anti-mouse antibody
(Dako, UK). Appropriate isotype controls were performedC
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MC-1 was repeated a minimum of 4 times and all 6 scFvs demonstrated
Cs when compared to E4 (representative of 3 independent experiments
Fig. 4 The effects of scFv A1 on mast cell adhesion. a HMC-1 adhesion
to monolayers of BEAS-2B human airway epithelial cells and primary
HASMCs was assessed in the presence of anti-mast cell scFv A1 or a
control scFv E4 which does not bind. Baseline adhesion and adhesion in
control media containing antibody vehicle (glycerol, final concentration
0.8-1.5 % depending on the scFv batch) is also shown. Plotted as
mean ± SEM for all experiments; n= 8 ASM donors used in independent
experiments and n= 4 independent experiments for BEAS-2B. *p = 0.048
compared to E4, **p= 0.008 compared to E4. b HLMC adhesion to
monolayers of BEAS-2B human airway epithelial cells and primary
HASMCs was assessed in the presence of anti-mast cell scFv A1 or a
control scFv E4 which does not bind. Baseline adhesion and adhesion in
control media containing antibody vehicle (glycerol, final concentration
0.8-1.5 % depending on the scFv batch) is also shown for HASMCs,
baseline adhesion is shown for BEAS-2B cells (glycerol not assessed).
Plotted as mean ± SEM for all experiments; n= 1 ASM donor and 7
HLMC donors used in n= 7 independent experiments, and n= 6 HLMC
donors in independent experiments for BEAS-2B. *p= 0.029 compared
to E4, # p = 0.017 compared to E4
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FITC (1:10 dilution).
Immunofluorescent staining
W1-AA677, E1-AA685 and control MCBS1 mouse mast
cells were grown on fibronectin-coated chamber slides
and labeled with the appropriate mAb or isotype control
as used for flow cytometry. A1 antibody was indirectly
labeled with 9E10 anti-myc secondary mouse mAb and
then RPE-labeled rabbit anti-mouse (Dako). Cells were
counterstained with 4′,6′-diamidino-2 phenylindole (DAPI,
Sigma, Gillingham, Dorset, UK) and the slide was mounted
using fluorescent mounting medium. Cells were visualized
using a computer imaging system (Cell F, Olympus,
Germany).
Adhesion assays
Based on saturation of staining identified using flow cy-
tometry, polyclonal pre- and post-immune rabbit sera
were incubated with HLMC cells at a 1:10 dilution, and
scFvs with HMC-1 and HLMCs at approximately 20 μg/ml
for 30 min at room temperature. HLMCs and HMC-1 cell
adhesion to BEAS-2B epithelial and primary HASMCs was
then assessed as described previously [5, 6].
Immunoprecipitation of scFv-bound mast cell ligand
For immunoprecipitation experiments, anti-C-myc 9E10
was covalently coupled to protein A/G Agarose using
the Pierce Crosslink Immunoprecipitation kit (Pierce)
using the manufacturer’s instructions. ScFv A1 and E4
(80 μg) were then bound to 80 μl of 50 % (v/v) 9E10-
proteinA/G agarose resin in 0.01 M sodium phosphate,
0.15 M NaCl; pH 7.2 for 16 h at 4 °C. Resin was washed
3 times in PBS and twice in lysis/wash buffer. HMC-1
membrane pellets were prepared as described above
from 1.6 × 107 cells and then solubilised in 1.2 ml of
lysis/wash buffer (0.025 M Tris, 0.15 M NaCl, 0.001 M
EDTA, 1 % NP-40, 5 % glycerol, pH 7.4) by incubation
on ice for 20 min. Samples were centrifuged (17000 g,
20 min, 4 °C) and supernatants collected. Pellets were
resuspended in the same buffer and incubated and cen-
trifuged as before. Supernatant was collected and pooled
with the previously obtained supernatant. Soluble native
HMC-1 membrane (400 μl) was applied to the scFv-
9E10-protein A/G agarose resin and allowed to bind at
RT for 5 h with rotating. In spin columns, the resin was
centrifuged (800 g, 10 s), resin was then washed 4 times
with 500 μl TBS and once with 200 μl of conditioning
buffer (Pierce Crosslink Immunoprecipitation kit). Pro-
tein was then eluted in three 100 μl volumes of a low
pH elution buffer (Pierce Crosslink Immunoprecipitation
kit). Immunoprecipitated proteins were separated on
SDS-PAGE gels and visualised by staining with Coom-
massie brilliant blue. The A1 specific band of interestwas excised and analysed by in-gel trypsin digestion
followed by peptide mass fingerprint using MALDI-ToF
mass spectrometry (service run by the Protein Nucleic
Acid Chemistry Laboratory, University of Leicester, UK).
Assessment of Kit phosphorylation in HMC-1
106 HMC-1 cells in 1 ml were treated with 20 μg/ml E4
or A1 antibody for 15 min at 37 °C, followed by 100 ng/ml
SCF for 3 min at 37 °C; 30 mg/lane of protein extract was
resolved in 4–12 % gradient SDS-PAGE gel transferred on
Gough et al. Respiratory Research  (2015) 16:86 Page 7 of 112 blots, probed with either pY99 [Santa Cruz, sc-7020],
anti-Kit E1 [Santa Cruz, sc-17806] and beta-actin C4
[Santa Cruz, sc-47778].
Statistical analysis
Differences in adhesion between experimental conditions
were examined using paired t tests where appropriate.
p < 0.05 was considered statistically significant.
Results
Polyclonal sera binding to HLMC and inhibition of HLMC
adherence to BEAS-2B bronchial epithelial cells
The polyclonal serum collected from two post-immune
rabbits labelled HLMCs clearly at dilutions from 1:10 to
1:10,000 when compared to control pre-immune serum
(Fig. 1). In addition, the post-immune sera from both
rabbits markedly inhibited HLMC adhesion to BEAS-2B
epithelial cells compared to pre-immune sera at a 1:10
dilution (n = 5 HLMC donors, p = 0.004 for both rabbits;
Fig. 2). The post-immune sera did not enhance histamine
release from HLMCs compared to the pre-immune sera
(data not shown).
ScFv-phage library production and selection of anti-
human mast cell scFv antibodies
An scFv library estimated to contain approximately 3.7 ×
107 different antibodies was produced from spleen cells of
the two rabbits immunised with HLMC and HMC-1
membrane fractions. ScFv-phage antibodies were selected
from the library over 3 or 4 rounds of selection in two in-
dependent experiments. The polyclonal scFv-phage iso-
lated after each round of selection clearly demonstrated
enrichment for binders to the HMC-1 cells (Fig. 3a and
data not shown). Individual phage clones were isolated
from panning rounds with a clear enrichment for binders
to HMC-1 (rounds 3 and 4). Monoclonal scFv were
assessed by phage-ELISA and those producing ELISA sig-
nals at least twice the background signal (produced in theFig. 5 Deduced amino acid sequence of the anti-mast cell scFv A1. The aliabsence of scFv-phage) were selected and the scFv genes
sequenced. Unique scFvs from these candidate mast cell
binders were produced as soluble antibodies within
HB2151 host cells and purified antibodies were assessed
for binding to HMC-1 by ELISA and flow cytometry. Six
distinct scFvs were identified that bound to HMC-1 and
did not bind to control Jurkat cells (Fig. 3b and c and data
not shown).
scFv A1 inhibits HMC-1 adhesion to HASMCs and BEAS-2B
epithelial cells
The final glycerol concentration in the adhesion assays
was between 0.8 and 1.5 % depending on the stock con-
centration of purified antibody. Glycerol did not affect
HMC-1 adhesion to either HASMCs or BEAS-2B cells,
or HLMC adhesion to HASMCs (glycerol not tested for
BEAS-2B cells) (Fig. 4). The six scFvs that displayed
binding to mast cells were assessed for their ability to in-
hibit HMC-1 adhesion to these cell types; the concentra-
tions used were based on saturation of staining identified
using flow cytometry. Of these antibodies, purified scFv
A1 at a concentration of approximately 20 μg/ml consist-
ently inhibited adhesion of HMC-1 cells to both HASMCs
(n = 8 donors used in independent experiments) and
the BEAS-2B epithelial cell line (n = 4 independent ex-
periments) (Fig. 4a). Adhesion of HMC-1 to HASMCs
was reduced from 43.4 ± 4.4 % in the presence of a
non-binding isotype control scFv (E4) to 22.3 ± 2.9 % in
the presence of A1 (p = 0.008). Adhesion of HMC-1 to
BEAS-2B cells was reduced from 58.4 ± 7.4 % in the
presence of E4 control scFv to 39.7 ± 2.4 % in the pres-
ence of A1 (p = 0.048).
scFv A1 also bound to HLMCs (Fig. 3d). Adhesion of
HLMCs to HASMCs was reduced from 42.9 ± 9.2 % in
the presence of E4 isotype control, to 25.8 ± 8.7 % in the
presence of A1 (p = 0.029, 7 independent experiments)
(Fig. 4b). Adhesion of HLMCs to BEAS-2B cells was re-
duced from 28.3 ± 3.1 % in the presence of E4 to 16.9 ±gnment is according to the method of Kabat et al. [18]
Fig. 6 Identification of Kit as the antigen for scFv A1. a
Immunoprecipitation of HMC-1 plasma membrane proteins with
scFv A1 identifed a unique band of approximately 145 kDa (arrow).
Analogous immunoprecipitations using scFvs C1 (anti-mast cell scFv) and
E4 (scFv with irrelevant binding) are shown for comparison. Excision and
sequencing demonstrated that this was Kit. bWestern blotting of protein
immunoprecipitated by scFv A1 demonstrated positive staining using an
anti-Kit antibody, with a doublet of the expected size for Kit (145/120 kDa).
c Flow cytometry histograms demonstrating that following incubation of
HMC-1 with SCF (100 ng/ml) for 15 min, binding of scFv A1 was
markedly reduced compared to control, in keeping with SCF-induced
Kit internalisation
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periments) (Fig. 4b). A1 at a concentration of 10 μg/ml
was less effective at inhibiting HMC-1 adhesion to
HASMCs than 20 μg/ml (30 ± 10 % inhibition [p = 0.12],
versus 65.3 ± 7.2 % respectively [p = 0.001], n = 4 inde-
pendent experiments). Four independent batches of anti-
bodies were used in the HASMC adhesion assays and
three independent batches in the BEAS-2B adhesion as-
says; the efficacy of A1 was similar across batches. Neither
A1 nor E4 released histamine from HMC-1 cells or
HLMCs (not shown). A1 did not alter HMC-1 viability
or cell numbers over 1, 6, 24 or 48 h compared to E4.
ScFv amino acid sequence
The anti-mast cell antibody A1 was analyzed by DNA
sequencing. The deduced amino acid sequences (Fig. 5)
shows that the antibody contains a kappa light chain com-
bined with VH1-a1 heavy chain. The E4 control antibody
was also sequenced and also contained a kappa light chain
combined with VH1-a1 heavy chain but with distinct CDR
regions compared to A1 (data not shown).
Immunoprecipitation and identification of the scFv A1 cell
surface antigen
To determine what scFv A1 binds to we first examined
Western blots of HMC-1 cells probed with A1 but no
staining was evident (not shown). We then used A1 for
the immunoprecipitation of HMC-1 proteins and obtained
a discreet band of approximately 145 kDa which was spe-
cific for immunoprecipitation with this scFv (Fig. 6a). Exci-
sion and sequencing of this band demonstrated that it was
Kit (CD117, SCF receptor). To confirm further that the
immunoprecipitated protein was Kit, we demonstrated that
a commercial Kit antibody detected the protein precipi-
tated by A1 in Western blot (Fig. 6b). Again, A1 did not
bind this protein in Western blots, indicating that A1 may
bind to Kit via a conformational epitope. In keeping with-
the observation that Kit is internalised following ligation
by SCF [22], binding of A1 to HMC-1 (analysed by flow
cytometry) was reduced when HMC-1 were exposed to
SCF 100 ng/ml (Fig. 6c). Importantly, A1 bound to human
Kit-expressing mouse MCBS1 cells [20] but not mock-
transduced or untransduced E1-AA685 or wild type cells
respectively (Fig. 7).
scFV A1 does not interfere with Kit signalling
Incubation of HMC-1 with A1 (20 μg/ml) did not induce
the phosphorylation of Kit or other intracellular proteins,
and did not inhibit SCF-dependent phosphorylation of Kit
or other intracellular proteins when compared to the con-
trol scFv E4 (Fig. 8). This suggests that A1 most likely
binds to Kit outside the SCF-binding domain. However,
epitope mapping will be required to confirm this.Discussion
By immunising rabbits with membrane proteins derived
from HLMC and HMC-1 cells, we were able to identify
scFv-expressing phage which bound to HMC-1 but not
Jurkat cells. Subsequent purification of several HMC-1-
Gough et al. Respiratory Research  (2015) 16:86 Page 9 of 11specific scFv antibodies identified an antibody, A1, that
binds to Kit, and which is able to attenuate HMC-1 and
HLMC adhesion to both HASMCs and BEAS-2B airway
epithelial cells.
Cell-cell adhesion is a fundamental mechanism through
which cells communicate. HLMC and HMC-1 adhere to
human airway epithelial cells, HASMCs and lung fibro-
blasts [5, 6, 8, 23], and human skin MCs and HMC-1 cells
adhere to skin fibroblasts [7]. In these previous studies,
extensive investigation was undertaken to identify the ad-
hesive mechanisms, but virtually all adhesion pathways
known at the time were not operative. However, we could
demonstrate that O-glycosylation was involved in the ad-
hesion of human MCs to airway epithelium [6]. Subse-
quently we showed that HLMCs and HMC-1 cells adhere
to HASMCs, and that this occurs in part via CADM1 [5].
Therefore much is still not known about the adhesive
mechanisms mediating the above interactions. In all of
these studies, the immature leukaemic HMC-1 cell line
shared similar adhesion properties to the differentiatedFig. 7 scFv1 A1 binds to human Kit-expressing MCBS1 mouse mast cells. Kit e
(b). a Fluorescent histograms (red lines), plotted with corresponding isotype c
human Kit-expressing mouse mast cell line, but not in E1-AA685 mock-tra
intensity was determined minus the total binding of matched isotype contro
independent experiments. b Immunofluorescent staining of W1-AA677, E1-AA
red (RPE); inset: isotype control. Representative of two independent experimecells from lung and skin. We therefore generated scFv
antibodies to human MC membrane proteins using the
technique of phage display in an attempt to identify
further adhesion pathways in HLMCs and HMC-1.
In mice, MC adhesion to fibroblasts is mediated in part
via MC-expressed c-kit binding to membrane-bound SCF
on fibroblasts [24], and in part by CADM1 expressed by
MCs acting heterophilically [25]. Human gut MCs adhere
to human umbilical vein endothelial cells (HUVEC) via a
Kit/SCF-dependent mechanism [26], which is attenuated
by function-blocking antibodies to either Kit or SCF,
indicating an adhesive interaction between Kit and
membrane-bound SCF. However, similar function-blocking
antibodies did not demonstrate a role for Kit/SCF in the ad-
hesion of HLMCs or HMC-1 cells to HASMCs or airway
epithelium [5, 6, 8], or human skin MCs or HMC-1cells
to skin fibroblasts [7]. Interestingly, our scFv antibody
A1 detects Kit, and partially attenuates HMC-1 and HLMC
adhesion to both BEAS-2B human airway epithelial cells
and HASMCs, suggesting that Kit-dependent adhesionxpression was confirmed by flow cytometry (a) and immunofluorescence
ontrols (blue line) demonstrate A1 and Kit expression in the W1-AA677
nsfected cells or non-transfected control cells. The mean fluorescent
ls for A1 and Kit, scFv E4 and mouse IgG respectively. Representative of 3
685 and control cells. Nuclei stained blue with DAPI, A1 and Kit stained
nts
Fig. 8 scFv A1 does not initiate or interfere with Kit signalling. HMC-1
were incubated with scFv A1 or E4 control in the presence or absence
of SCF 100 ng/ml. Total intracellular phosphorylation assessed by
Western blotting (PY99 antibody) was not altered by A1 in either
the absence or presence of SCF. Phosphorylation of Kit (bands
145/120 kDa) in the left panel was also not altered. Staining for Kit
(E1, right panel) and β-actin demonstrates equal loading for Kit within
each pair of experiments. Representative of three independent
experiments
Gough et al. Respiratory Research  (2015) 16:86 Page 10 of 11does in fact contribute to HMC-1 adhesion to these
cells. Because A1 does not interfere with SCF-dependent
Kit signalling, and because several studies have shown
that function-blocking SCF/Kit antibodies do not inhibit
HMC-1, HLMC or skin MC adhesion, it is likely that the
A1 antibody binds outside the SCF binding domain on
Kit. If true, then this indicates the presence of a novel ad-
hesion epitope on human Kit, which mediates adhesion
via a counter-receptor which is not SCF.
Such a mechanism is highly plausible because Kit is a
type III receptor tyrosine kinase which is a member of
the immunoglobulin (Ig) superfamily, with 5 extracellu-
lar Ig-like domains. The SCF binding site is situated in
the three N terminal Ig domains, with the core in the
second domain [27]. Kit is potentially glycosylated at N
and O glycosylation sites although the nature of Kit gly-
cosylation is poorly defined. Both N and O glycans are
involved in adhesion mediated by many receptors. Our
A1 antibody was only able to detect native Kit as shown
by immunoprecipitation and flow cytometry, and not
under reducing conditions used for Western blotting.
This suggests that this antibody recognises a distinct
conformational epitope.
Conclusions
In summary, we have generated a Kit-specific antibody
which partially attenuates human MC adhesion to both hu-
man airway epithelial cells and HASMCs. Our results indi-
cate that Kit may contribute to these adhesion pathways viaa previously unidentified adhesion epitope. Targeting this
adhesion pathway might offer a novel approach for the
inhibition of MC interactions with structural airway
cells, without detrimental effects on Kit signalling in
other tissues.
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